Wed, Mar 4, 2015, 12:01 AM EST - U.S. Markets open in 9 hrs 29 mins

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

tnk.shorting 7 posts  |  Last Activity: Jan 15, 2015 2:26 PM Member since: Feb 29, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tnk.shorting by tnk.shorting Jan 15, 2015 2:26 PM Flag

    As some old timers here may recall, Dirk gave SYNERGY a thumbs down prior to readout. I got numerous thumbs down here for relaying Dirk's negative tweet, but Dirk ended up being right. Since I never was a custirsen believer, I actually bought more OGXI shares on the basis of apatorsen's potential - which is why I'm not happy about Dirk's latest tweet about OGXI,. Does anyone know what "recent data" Dirk is referring to?

    Dirk Haussecker ‏@RNAiAnalyst 3h3 hours ago
    @WilliamGerber1 @redacre beware $ogxi, recent $ISIS data support that very hard to get knockdown in tumor cells (unlike microenvironment).

  • Reply to

    It supposed to be 'GOOD' news today

    by lefty_rosenthal7 Dec 19, 2014 4:56 PM
    tnk.shorting tnk.shorting Dec 19, 2014 6:29 PM Flag

    IMO, today was not good news. It appears that the trial failed (overall HR too high). As with SYNERGY, they drilled down into the data to look for benefits among subgroups, and they found what they were looking for. The benefit they found may or may not be real. However, I'm not sure how they'll know for sure without another lengthy and expensive trial. Who's going to pay for it?

    I'd like to see more data - specifically, PFS and OS data expressed in months: How much longer did the treatment arm and subgroup survive? If the benefit of Apatorsen was short-lived, who would want to invest in a Phase 3 trial?

    Fortunately, there are many more Phase 2 Apatorsen (and a few more Custirsen) trials that can still move the ball downfield in the event of good news. But as for today, I'm not sure why Needham felt this was a reason to encourage investors to buy. I'm already long OGXI, but won't be buying more or selling until management gives us a more complete picture of how the Borealis-1 patients fared.

  • tnk.shorting tnk.shorting Oct 3, 2014 7:56 PM Flag

    Only shares Cormack sold were for withholding taxes on stock options. But Cormack is a liar - just like you. I gave up trying to post my transcript of the conference call since Yahoo censors won't let it in for some reason. However, anyone who listened to the cc was promised an "exciting presentation" at ESMO with details about how sicker patients " did, in fact, live longer on custirsen as we talked about in the prepared statement." As the PPS shows, the ESMO abstract did not corroborate Cormack's representations. Played again..

    For those who don't frequent the ISIS board, you and your many aliases are Darkster, and, no, you never posted any messages about selling OGXI at $22. Not sure who's the bigger liar: you or Cormack.

  • Reply to

    August 7 Conference Call

    by tnk.shorting Oct 3, 2014 5:41 PM
    tnk.shorting tnk.shorting Oct 3, 2014 5:44 PM Flag

    So, my question is, is there more info coming down the pike?

  • tnk.shorting by tnk.shorting Oct 3, 2014 5:41 PM Flag

    I posted Cormack's statements in another thread, but, for some reason, Yahoo didn't let them stick. Trying again:

    Cormack's prepared statement on conference call:

    Final data from the Phase 3 SYNERGY trial will be presented next month at the ESMO conference. Over the past several months, we have been working closely with investigators to thoroughly understand these results, Our subsequent exploratory analysis suggests that patients in the SYNERGY trial who had the worst poor-prognostic factors and received custirsen treatment appeared to have lived longer. This supports our belief in evaluating custirsen in patients who typically have a poor prognosis and are exposed to more treatments prior to treatment with custirsen such as patients in the second-line chemotherapy CRPC AFFINITY trial.

  • tnk.shorting tnk.shorting Oct 3, 2014 5:38 PM Flag

    Chad Messer: "Alright, great, thanks, [I'll] look forward to seeing that data."

    Cormack: "Yeah, it'll be an exciting presentation, and we'd love to do some follow up, obviously, after that data that is available [is] in the public domain, and be able to speak to it."

  • tnk.shorting tnk.shorting Oct 3, 2014 5:36 PM Flag

    I'm scratching my head as I try to reconcile what management publicly stated on the 8/7/2014 conference call with the anti-climactic ESMO abstract, Is more information forthcoming? Following is my transcription of the SYNERGY-relevant portions of the conference call. Can anyone corroborate Cormack's statements?

ALNY
106.91+1.51(+1.43%)Mar 3 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.